🔗 Share this article

Given that the US proceeds with unprecedented revisions to its immunization recommendations, an unexpected name has emerged unexpectedly: Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who first made her name by casting doubt on Covid shots during the pandemic and has zeroed in on alleged deaths following COVID-19 vaccination in her short position at the US Food and Drug Administration (FDA).

Scheduled Changes to Childhood Vaccine Program

Agency leaders had intended to reveal major changes to the pediatric vaccine schedule recently, bringing the US with the Danish immunization schedule, sources say – a major change that would put the US out of alignment with much of the international standard with little proof for benefit. The announcement has been postponed until the coming year.

In place of Vinay Prasad, Dr. Høeg is set to speak at the event. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the office this year.

A Shift at the Regulatory Body

Høeg's temporary position may indicate a closer partnership between the drug and biologics divisions as Høeg and Dr. Prasad consolidate power at the FDA – and it signals a greater focus upon rolling back long-standing immunizations at the FDA.

Høeg has often pushed for ending certain childhood immunization guidelines in the US so as to align more in line with the Danish model, a society with universal health coverage and a citizenry roughly the size of Wisconsin’s.

So far comments, she has persisted in emphasizing on vaccines – usually the purview of Dr. Prasad, director of the FDA’s CBER – rather than medication approval.

Questions Over Background

The appointee has little discernible background in drug development, oversight or management, which has been standard for past directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the commissioner and CBER since spring.

“It seems she lacks to have the requisite experience” for overseeing the pharmaceutical oversight division, stated Jonathan Howard. “She’s never run a scientific study. She is not versed in running a major agency. She has no expertise in drug approvals.”

Previous commissioners of the center would “be deeply familiar with regulatory frameworks and the science of medication creation”, noted Janet Woodcock. “Frankly, she doesn’t have the sort of resume that prior appointees who led the center have had.”

CDER has an vast range of responsibilities at the agency, she emphasized.

“Everybody just zeroes in on the innovative therapies, but the generic program clears thousands of generic drugs. There is also a biosimilars division, OTC medication office and more, and all of those must be looked after,” she said. “The area you overlook, that’s the thing that I always told people is going to cause problems.”

There is also, a significant leadership aspect to the position, which supervises in excess of 5,000 employees. “It is a enormous leadership role, if you execute it properly,” Woodcock concluded.

Response and Disputed Policies

When asked about concerns about Dr. Høeg's qualifications and whether this assignment represents increased cooperation among agency officials on immunizations, a representative stated that the “questions stem from inaccurate presumptions”.

“Her resume matches the responsibilities of her job,” the spokesperson said, noting the time Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Dr. Høeg inherits the commissioner’s recently launched priority voucher program, a controversial one-day drug-approval program that allegedly troubled her former heads. “By what process are these medications being selected for this voucher program? Who takes the choices?” Howard said. “There’s a lot of lack of transparency happening at the FDA right now.”

Overall, he remarked, “the Food and Drug Administration looks to be trending towards less stringent rules of most medications, with the exception of vaccines.”

Public History on Vaccines

Regarding immunizations, Dr. Høeg has a more documented, if concerning, past, critics have noted. She released a analysis using unverified volunteer-provided data to estimate the frequency of myocarditis after Covid immunization. She advised the state of Florida top health official Dr. Joseph Ladapo, who was said to have modified findings to indicate COVID-19 vaccines are more dangerous than they are.

Among her “policy goals” for the new federal leadership encompassed altering guidelines for novel immunizations and halting “optional” vaccines, she stated post-election on a online show. At the agency, Dr. Høeg has according to sources suggested preventing adolescent males from receiving COVID-19 vaccinations.

“She’s an all-around true believer who starts off with her conclusions and works backwards to retrofit the data in a extremely disingenuous, dishonest manner,” Howard stated.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of fellow skeptics, {like|